• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

子宫内膜癌和宫颈癌患者的失败模式及随访程序的价值

Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients.

作者信息

Sartori E, Pasinetti B, Carrara L, Gambino A, Odicino F, Pecorelli S

机构信息

Department of Gynecology and Obstetrics, University of Brescia, Brescia, Italy.

出版信息

Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S241-7. doi: 10.1016/j.ygyno.2007.07.025. Epub 2007 Sep 10.

DOI:10.1016/j.ygyno.2007.07.025
PMID:17826824
Abstract

OBJECTIVE

The aim of this study was to evaluate the outcome benefit of follow-up protocols for patients with recurrent endometrial and cervical cancer.

METHODS

A retrospective review on patients primarily treated at the Division of Gynecologic Oncology, University of Brescia, was performed. We focused our attention on recurrent patients and we evaluated the pattern of relapse and the presence of symptoms or signs of disease at recurrence and evidence of disease on routine follow-up test or visits.

RESULTS

The vast majority of recurrences occurred within the first 3 years after primary treatment (78% and 87% in endometrial and cervical cancers, respectively). A better overall survival from relapse was observed when vaginal relapse was compared to other sites in endometrial cancer patients and when pelvic recurrence was compared to distant sites in cervical cancer cases. Recurrent endometrial and cervical cancer patients were symptomatic in 52% and 65% of cases, respectively. Among asymptomatic recurrent endometrial cancer cases, pelvic examination, abdominal or pelvic ultrasound and CT could detect 92% of relapses, while the vast majority of cervical cancer relapses could be diagnosed by pelvic examination and/or CT (85%).

CONCLUSION

Endometrial cancer patients showed a significantly better prognosis when the recurrence was detected during follow-up visits, thus supporting the real advantage of our surveillance programs, while no statistically significant differences were found in survival of cervical cancer patients between the symptomatic and the asymptomatic group.

摘要

目的

本研究旨在评估复发性子宫内膜癌和宫颈癌患者随访方案的疗效益处。

方法

对主要在布雷西亚大学妇科肿瘤学部门接受治疗的患者进行回顾性研究。我们将注意力集中在复发患者身上,评估复发模式、复发时疾病症状或体征的存在情况以及常规随访检查或就诊时的疾病证据。

结果

绝大多数复发发生在初次治疗后的前3年内(子宫内膜癌和宫颈癌分别为78%和87%)。在子宫内膜癌患者中,与其他部位复发相比,阴道复发时观察到从复发开始有更好的总生存期;在宫颈癌病例中,与远处复发相比,盆腔复发时观察到更好的总生存期。复发性子宫内膜癌和宫颈癌患者分别有52%和65%出现症状。在无症状的复发性子宫内膜癌病例中,盆腔检查、腹部或盆腔超声以及CT可检测到92%的复发,而绝大多数宫颈癌复发可通过盆腔检查和/或CT诊断(85%)。

结论

当在随访就诊期间检测到复发时,子宫内膜癌患者的预后明显更好,从而支持了我们监测方案的实际优势,而在有症状和无症状的宫颈癌患者生存方面未发现统计学上的显著差异。

相似文献

1
Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients.子宫内膜癌和宫颈癌患者的失败模式及随访程序的价值
Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S241-7. doi: 10.1016/j.ygyno.2007.07.025. Epub 2007 Sep 10.
2
Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis.后续不同的检查方式能否在无症状宫颈癌复发诊断中发挥作用?一项意大利多中心回顾性分析。
Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S150-4. doi: 10.1016/j.ygyno.2007.07.028. Epub 2007 Sep 14.
3
Posttherapy surveillance of women with cervical cancer: an outcomes analysis.宫颈癌女性的治疗后监测:一项结果分析。
Gynecol Oncol. 2000 Aug;78(2):187-93. doi: 10.1006/gyno.2000.5860.
4
[Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)].盆腔淋巴结清扫术作为早期子宫内膜癌(I期)中复发性淋巴转移高风险患者辅助放疗的替代方案
Minerva Ginecol. 2009 Feb;61(1):1-12.
5
Costs and benefits of routine follow-up after curative treatment for endometrial cancer.子宫内膜癌根治性治疗后常规随访的成本与效益
CMAJ. 1997 Oct 1;157(7):879-86.
6
[Analysis of risk factors for recurrence after treatment of endometrial uterine cancer].[子宫内膜癌治疗后复发的危险因素分析]
Ginekol Pol. 2009 Sep;80(9):687-93.
7
Recurrent endometrial cancer: a retrospective study.复发性子宫内膜癌:一项回顾性研究。
Eur J Obstet Gynecol Reprod Biol. 2007 Jan;130(1):114-20. doi: 10.1016/j.ejogrb.2005.12.014. Epub 2006 Feb 3.
8
Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme.复发性子宫内膜癌的监测:随访方案的制定
Gynecol Oncol. 1995 Nov;59(2):221-5. doi: 10.1006/gyno.1995.0012.
9
Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma.国际妇产科联盟(FIGO)I/II期子宫内膜腺癌患者的术后监测
Gynecol Oncol. 1995 Oct;59(1):20-4. doi: 10.1006/gyno.1995.1262.
10
Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness.鳞状细胞癌抗原在宫颈癌放疗随访中的应用:成本效益评估
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1145-9. doi: 10.1016/j.ijrobp.2007.04.055. Epub 2007 Aug 6.

引用本文的文献

1
Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022) - Part 2 with Recommendations on the Therapy of Precancerous Lesions and Early-stage Endometrial Cancer, Surgical Therapy, Radiotherapy and Drug-based Therapy, Follow-up Care, Recurrence and Metastases, Psycho-oncological Care, Palliative Care, Patient Education, and Rehabilitative and Physiotherapeutic Care.子宫内膜癌。德国妇科与产科学会(DGGG)、德国妇科肿瘤学会(DKG)和德国妇科与产科学会(DKH)指南(S3级,德国医学科学院注册编号032/034-OL,2022年9月) - 第2部分,关于癌前病变和早期子宫内膜癌的治疗、手术治疗、放射治疗和药物治疗、随访、复发与转移、心理肿瘤护理、姑息治疗、患者教育以及康复和物理治疗的建议。
Geburtshilfe Frauenheilkd. 2023 Aug 15;83(8):963-995. doi: 10.1055/a-2066-2068. eCollection 2023 Aug.
2
Management for Cervical Cancer Patients: A Comparison of the Guidelines from the International Scientific Societies (ESGO-NCCN-ASCO-AIOM-FIGO-BGCS-SEOM-ESMO-JSGO).宫颈癌患者的管理:国际科学学会(ESGO-NCCN-ASCO-AIOM-FIGO-BGCS-SEOM-ESMO-JSGO)指南比较
Cancers (Basel). 2024 Jul 15;16(14):2541. doi: 10.3390/cancers16142541.
3
The long game: Telemedicine patient satisfaction metrics and methods of recurrence detection for gynecologic cancer patients throughout the initial year of the COVID-19 pandemic.长远之计:新冠疫情大流行首年期间妇科癌症患者的远程医疗患者满意度指标及复发检测方法
Gynecol Oncol Rep. 2022 Jul 8;42:101037. doi: 10.1016/j.gore.2022.101037. eCollection 2022 Aug.
4
Patterns of Recurrent Disease in Cervical Cancer.宫颈癌复发疾病模式
J Pers Med. 2022 May 6;12(5):755. doi: 10.3390/jpm12050755.
5
Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review.2018FIGO 期 IIIC 宫颈癌的治疗策略和预后因素:综述。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221086403. doi: 10.1177/15330338221086403.
6
Modified Houdek vault applicator for high-dose-rate brachytherapy: a technical report and case series.用于高剂量率近距离放射治疗的改良侯德克穹顶施源器:技术报告及病例系列
J Contemp Brachytherapy. 2021 Dec;13(6):649-654. doi: 10.5114/jcb.2021.112116. Epub 2021 Dec 30.
7
The Cost of Locally Advanced Cervical Cancer in Thailand: an Empirical Study for Economic Analysis.泰国局部晚期宫颈癌的成本:一项经济分析的实证研究。
Asian Pac J Cancer Prev. 2021 Oct 1;22(10):3171-3179. doi: 10.31557/APJCP.2021.22.10.3171.
8
Cancer of the corpus uteri: 2021 update.子宫体癌:2021年更新
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):45-60. doi: 10.1002/ijgo.13866.
9
The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer.宫颈癌患者个体化监测策略的年度复发风险模型。
Eur J Cancer. 2021 Oct 16;158:111-122. doi: 10.1016/j.ejca.2021.09.008.
10
Long-term outcomes of cervical cancer patients with complete metabolic response after definitive chemoradiotherapy.根治性放化疗后完全代谢缓解的宫颈癌患者的长期结局。
J Gynecol Oncol. 2021 Sep;32(5):e74. doi: 10.3802/jgo.2021.32.e74.